SYSNAV Healthcare Announces EMA Primary Endpoint Qualification of Stride Velocity 95th Centile (SV95C) for Duchenne Muscular Dystrophy ...Middle East

EMA opinion marks the first qualification of a digital outcome measure for use as a primary endpoint in pivotal drug trials SV95C is an objective, real-world digital ambulation measure of top performance, informing more confident treatment decision-making and streamlining drug...

Hence then, the article about sysnav healthcare announces ema primary endpoint qualification of stride velocity 95th centile sv95c for duchenne muscular dystrophy was published today ( Tuesday 08/08/2023 - 07:45 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( SYSNAV Healthcare Announces EMA Primary Endpoint Qualification of Stride Velocity 95th Centile (SV95C) for Duchenne Muscular Dystrophy )

Also on site :

• Who Is Anthony Kazmierczak? Ilhan Omar Attack Suspect Identified
• “The Nation” Nominates Minneapolis for the Nobel Peace Prize
• R&B Legend's Global Tour With Akon Announced